Health Care International - New Boehringer Ingelheim Data To Be Presented On Health-Related Quality Of Life With Afatinib In Patients With EGFR Mutation-Positive Advanced NSCLC
Boehringer Ingelheim has announced new patient-reported health-related outcomes for its investigational oncology compound afatinib,* including lung cancer-related symptoms and quality of life (QoL). These data are secondary endpoints of LUX-Lung 3,
Comments